Circulating tumor cell detection in high-risk non-metastatic prostate cancer

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 12, 2014, Pages 2157-2162

  Loh, Jasmin ^a   Jovanovic, Lidija ^b   Lehman, Margot ^c,d   Capp, Anne ^a   Pryor, David ^c,d   Harris, Monica ^a   Nelson, Colleen ^b   Martin, Jarad ^a  

^a CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Biomarkers; CellSearch; Circulating tumor cells; CTC; High risk non metastatic prostate cancer

Indexed keywords

AGED; HUMAN; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RISK; TUMOR EMBOLISM;

AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS; RISK;

EID: 84925229876     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1775-3     Document Type: Article

References (24)

1. Attard G et al (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69:2912–2918. doi:10.1158/0008-5472.CAN-08-3667
2. Bastian PJ et al (2007) Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res 13:5361–5367. doi:10.1158/1078-0432.CCR-06-2781
3. Cohen SJ et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221. doi:10.1200/JCO.2007.15.8923
4. Cristofanilli M et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791. doi:10.1056/NEJMoa040766
5. Danila DC et al (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:7053–7058. doi:10.1158/1078-0432.CCR-07-1506
6. Darshan MS et al (2011) Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 71:6019–6029. doi:10.1158/0008-5472.CAN-11-1417
7. Davis JW et al (2008) Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol 179:2187–2191. doi:10.1016/j.juro.2008.01.102 discussion 2191
8. de Bono JS et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309. doi:10.1158/1078-0432.CCR-08-0872
9. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I (2006) The detection of bone metastases in patients with high-risk prostate cancer: 99 mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47:287–297
10. Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619–626
11. Hou JM et al (2012) Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 30:525–532. doi:10.1200/JCO.2010.33.3716
12. Kats-Ugurlu G et al (2009) Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. J Pathol 219:287–293. doi:10.1002/path.2613
13. Lecouvet FE et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75. doi:10.1016/j.eururo.2012.02.020
14. Lilleby W, Stensvold A, Mills IG, Nesland JM (2013) Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients. Int J Cancer 133:149–155. doi:10.1002/ijc.28002
15. Liotta LA, Saidel MG, Kleinerman J (1976) The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 36:889–894
16. Ma X et al (2014) Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis. Tumour Biol. doi:10.1007/s13277-014-1731-5
17. Molnar B, Ladanyi A, Tanko L, Sreter L, Tulassay Z (2001) Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 7:4080–4085
18. Resel Folkersma L, San Jose Manso L, Galante Romo I, Moreno Sierra J, Olivier Gomez C (2012) Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. Urology 80:1328–1332. doi:10.1016/j.urology.2012.09.001
19. Schwarzenbach H, Alix-Panabieres C, Muller I, Letang N, Vendrell JP, Rebillard X, Pantel K (2009) Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 15:1032–1038. doi:10.1158/1078-0432.CCR-08-1910
20. Selth LA et al (2013) Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 109:641–650. doi:10.1038/bjc.2013.369
21. Spizzo G et al (2011) EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol 64:415–420. doi:10.1136/jcp.2011.090274
22. Stott SL et al (2010) Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2:25ra23. doi:10.1126/scitranslmed.3000403
23. Thalgott M et al (2013) Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol 139:755–763. doi:10.1007/s00432-013-1377-5
24. Wang MC, Valenzuela LA, Murphy GP, Chu TM (1979) Purification of a human prostate specific antigen. Invest Urol 17:159–163